Lenalidomide Eugia

Lenalidomide, the active ingredient in Lenalidomide Eugia, is an immunomodulatory agent (IMiD) presented as an oral tablet for systemic use. It is employed in the treatment of certain blood cancers, including multiple myeloma, myelodysplastic syndromes with a 5q deletion, and mantle‑cell lymphoma, primarily in adult patients.

GNH USA supplies Lenalidomide Eugia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomide is used in hematologic malignancies that involve abnormal plasma‑cell or lymphoid proliferation. - Multiple myeloma: reduces disease progression and improves survival in adult patients. - Myelodysplastic syndromes with 5q deletion: induces transfusion independence and cytogenetic remission. - Mantle cell lymphoma: provides disease control in relapsed or refractory cases.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Neutropenia: lowered neutrophil count increasing infection risk. - Thrombocytopenia: reduced platelet count leading to easy bruising. - Anemia: decreased red blood cells causing weakness. - Diarrhea: loose stools that may require management. - Rash: mild skin irritation or redness.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe neutropenia: markedly low neutrophils with fever. - Severe thrombocytopenia: dangerous platelet depletion with bleeding. - Secondary primary malignancies: emergence of new cancers. - Hepatic failure: significant liver enzyme elevation or dysfunction. - Stevens‑Johnson syndrome: severe skin reaction with blistering.

Before initiating Lenalidomide therapy, several safety considerations should be reviewed. - Pregnancy contraindication: drug is teratogenic; avoid use in pregnant women and ensure effective contraception. - Thrombosis risk: assess for prior clotting events; consider prophylactic anticoagulation when appropriate. - Hematologic monitoring: perform regular complete blood counts to detect neutropenia, thrombocytopenia or anemia. - Renal and hepatic function: evaluate organ function and adjust therapy if impairment is present. - Drug interaction vigilance: review concomitant medications for CYP3A4 modulators and anticoagulants. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and light.

Lenalidomide can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase lenalidomide exposure. - Thalidomide: combined use raises risk of severe teratogenicity and peripheral neuropathy. - Anticoagulants (warfarin, direct oral anticoagulants): heightened bleeding risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce lenalidomide levels. - NSAIDs: can increase risk of gastrointestinal bleeding when combined with anticoagulants. - Live vaccines: immunomodulatory effect may diminish vaccine efficacy or increase infection risk.